BUZZ-Emergent BioSolutions Inc: To develop cancer drug with MorphoSys
** Drugmaker's shares up 21 pct at $28.42 premarket
** Signs agreement with Germany's MorphoSys AG to develop and market its antibody targeting prostate cancer cells
** Emergent to get upfront payment of $20 million and potential milestone payments of up to $163 million
** Plans to start early-stage trial in prostate cancer patients within six months
** Emergent to get marketing rights in North America and MorphoSys in the rest of the world
© Thomson Reuters 2017 All rights reserved.